Study Comparing the Standard Administration of IO Versus the Same IO Administered Each 3 Months in Patients With Metastatic Cancer in Response After 6 Months of Standard IO
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Lung Cancer Metastatic|Renal Cell Carcinoma|Head and Neck Cancer|Bladder Cancer|Triple Negative Breast Cancer|Merkel Cell Carcinoma|Hepatocellular Carcinoma|Melanoma
Interventions: DRUG: Reduced dose intensity of IO
Sponsor: UNICANCER